Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(5):411-412; doi:10.1093/jnci/djh066
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lamont, E. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lamont, E. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?

Elizabeth B. Lamont

Correspondence to: Elizabeth B. Lamont, MD, MS, Massachusetts General Hospital Cancer Center, 55 Fruit St., Suite: Zero Emerson Place, Boston, MA 02114 (e-mail: elamont@partners.org)

The first 10% of the full text of this article appears below.

We appreciate Drs. Muñoz and Samet's careful review of our manuscript and the opportunity to provide additional details and results from our work. They have one main methodologic concern and several related empiric statistical questions regarding our study. Their overarching methodologic concern is that multivariable regression may not be able to adjust appropriately for the extreme differences in prognostically important covariates (e.g., race, income, tumor site, extent . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?